At Affimed, we are committed to improving outcomes for patients with cancer. Our scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unique approach to fighting cancer. With our unparalleled expertise in innate immunity and innate cell engager-based medicines, we aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies. Source
No articles found.
The Ensign Group, Inc.'s independent operating subsidiaries provide a broad spectr...
The Ensign Group, Inc.'s independent operating ...
Adverum is a clinical-stage gene therapy company targeting unmet medical need in o...
Adverum is a clinical-stage gene therapy compan...
Spark Therapeutics, a fully integrated company, strives to challenge the inevitabi...
Spark Therapeutics, a fully integrated company,...
Eclipes Diagnostics develops CANABINOX, a handheld testing device that can accurat...
Eclipes Diagnostics develops CANABINOX, a handh...
Fluidigm (NASDAQ:FLDM) is an industry-leading biotechnology tools provider with a ...
Fluidigm (NASDAQ:FLDM) is an industry-leading b...
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting ...
Integra LifeSciences, a world leader in medical...
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the develo...
Puma Biotechnology, Inc. is a biopharmaceutical...
We are a pharmaceutical company dedicated to the development of best-in-class ther...
We are a pharmaceutical company dedicated to th...
MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedica...
MorphoSys (FSE & NASDAQ: MOR) is a clinical-sta...
Join the National Investor Network and get the latest information with your interests in mind.